James M Ford Selected Research

iniparib

1/2017	Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.
1/2016	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
6/2015	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James M Ford Research Topics

Disease

55	Neoplasms (Cancer) 01/2022 - 01/2003
25	Breast Neoplasms (Breast Cancer) 01/2022 - 02/2004
13	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 10/2002
13	Triple Negative Breast Neoplasms 01/2020 - 04/2009
10	Stomach Neoplasms (Stomach Cancer) 01/2020 - 06/2007
10	Adenocarcinoma 11/2019 - 08/2005
7	Pancreatic Neoplasms (Pancreatic Cancer) 04/2017 - 10/2005
5	Genomic Instability 01/2016 - 08/2006
4	Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer) 01/2016 - 07/2011
3	Ovarian Neoplasms (Ovarian Cancer) 01/2019 - 07/2008
3	Microsatellite Instability 08/2012 - 07/2008
3	Li-Fraumeni Syndrome 08/2012 - 10/2002
3	Xeroderma Pigmentosum (Kaposi's Disease) 02/2012 - 10/2002
3	Carcinoma (Carcinomatosis) 01/2012 - 06/2008
2	Lung Neoplasms (Lung Cancer) 01/2022 - 04/2017
2	Carcinogenesis 01/2022 - 07/2015
2	Pathologic Complete Response 01/2020 - 01/2016
2	Residual Neoplasm 01/2016 - 11/2013
2	Neoplasm Metastasis (Metastasis) 08/2014 - 01/2013
1	Bile Reflux 01/2022
1	Gastritis 01/2022
1	Polyps 01/2022
1	Disease Progression 01/2022
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022
1	Adenoma (Adenomas) 01/2022
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021
1	Chronic Hepatitis B 12/2020
1	Infections 12/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2019
1	Undiagnosed Diseases 10/2019
1	Acquired Immunodeficiency Syndrome (AIDS) 11/2018
1	Colonic Neoplasms (Colon Cancer) 01/2017
1	Prostatic Neoplasms (Prostate Cancer) 11/2015
1	Cicatrix (Scar) 05/2015
1	Endometrial Neoplasms (Endometrial Cancer) 11/2014

Drug/Important Bio-Agent (IBA)

14	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2010
11	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2002
8	Gemcitabine FDA Link 01/2017 - 11/2008
7	Poly(ADP-ribose) Polymerase InhibitorsIBA 04/2017 - 09/2010
7	Progesterone Receptors (Progesterone Receptor)IBA 06/2015 - 04/2009
6	Biomarkers (Surrogate Marker)IBA 05/2015 - 08/2006
6	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 12/2010 - 04/2009
5	Hormones (Hormone)IBA 04/2018 - 08/2009
5	Estrogen ReceptorsIBA 06/2015 - 10/2010
4	NucleotidesIBA 01/2022 - 05/2014
4	PlatinumIBA 01/2020 - 05/2015
4	Cadherins (E-Cadherin)IBA 10/2016 - 06/2007
4	Fluorouracil (Carac)FDA LinkGeneric 07/2011 - 01/2003
3	EnzymesIBA 01/2022 - 04/2009
3	ErbB Receptors (EGF Receptor)IBA 01/2017 - 06/2011
3	iniparibIBA 01/2017 - 06/2015
3	Cisplatin (Platino)FDA LinkGeneric 01/2016 - 10/2010
2	Adenosine Triphosphate (ATP)IBA 11/2019 - 01/2016
2	Pharmaceutical PreparationsIBA 12/2017 - 01/2012
2	Trastuzumab (Herceptin)FDA Link 01/2017 - 01/2012
2	Carboplatin (JM8)FDA LinkGeneric 01/2017 - 06/2015
2	Epithelial Cell Adhesion MoleculeIBA 01/2016 - 05/2014
2	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 11/2015 - 07/2015
2	Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA 08/2014 - 01/2012
2	Small Interfering RNA (siRNA)IBA 08/2014 - 10/2010
2	Irinotecan (Camptosar)FDA LinkGeneric 02/2014 - 01/2003
2	ParaffinIBA 06/2012 - 01/2012
2	A-Form DNA (A-DNA)IBA 02/2012 - 04/2009
2	Phenobarbital (Luminal)FDA Link 10/2010 - 04/2009
2	human ERBB2 proteinIBA 10/2010 - 10/2010
2	antineoplaston A10 (A 10)IBA 07/2008 - 02/2004
1	Sucralfate (Carafate)FDA LinkGeneric 01/2022
1	2- (3- (2- (1- isopropyl- 3- methyl- 1H- 1,2- 4- triazol- 5- yl)- 5,6- dihydrobenzo(f)imidazo(1,2- d)(1,4)oxazepin- 9- yl)- 1H- pyrazol- 1- yl)- 2- methylpropanamideIBA 01/2022
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2022
1	nilotinib FDA Link 01/2022
1	ChromatinIBA 01/2022
1	Calcibiotic Root Canal SealerIBA 01/2022
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2022
1	DDBIBA 01/2021
1	NucleosidesIBA 12/2020
1	entecavir FDA Link 12/2020
1	GuanineIBA 11/2019
1	8-oxodeoxyguanosine triphosphateIBA 11/2019
1	8-oxodGTPaseIBA 11/2019
1	hydrogen sulfite (bisulfite)IBA 01/2019
1	AnthracyclinesIBA 04/2018
1	taxaneIBA 04/2018
1	VimentinIBA 12/2017
1	Interferon-betaIBA 12/2017
1	Ado-Trastuzumab EmtansineIBA 01/2017
1	TensinsIBA 11/2015
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 11/2015

Therapy/Procedure

21	Therapeutics 01/2022 - 01/2003
17	Drug Therapy (Chemotherapy) 01/2022 - 05/2005
9	Radiotherapy 01/2018 - 01/2003
6	Gastrectomy 01/2022 - 06/2007
6	Neoadjuvant Therapy 04/2018 - 01/2013
3	Precision Medicine 01/2020 - 01/2017
3	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 03/2012 - 10/2005
3	Conformal Radiotherapy 03/2012 - 01/2003
2	Chemoprevention 07/2015 - 11/2014
2	Prophylactic Mastectomy 09/2005 - 02/2004
1	Immunotherapy 01/2022
1	Genomic Medicine 10/2019
1	Adjuvant Chemotherapy 01/2018